Select Page
Statements on Takeda Clinical Trial (TAK-883-3001)

Statements on Takeda Clinical Trial (TAK-883-3001)

From the Desk of Miriam O’Day, President & CEO of the Alpha-1 Foundation: “It is with extreme disappointment that the Alpha-1 Foundation received the news that the Takeda Clinical Trial will not proceed forward at this time. The Foundation has every...
BIOPHARMA LEADERS UNITE TO STAND WITH SCIENCE

BIOPHARMA LEADERS UNITE TO STAND WITH SCIENCE

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines  NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX),...
Vaccine Allocation NAS Advisory Group Letter

Vaccine Allocation NAS Advisory Group Letter

September 4, 2020 Committee on Equitable Allocation of Vaccine for the Novel Coronavirus; National Academy of Medicine; National Academies of Sciences, Engineering, and Medicine RE: Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19...